Ownership & Editorial Policy
Peptide Press is owned by the principals of Peptinexia LLC, a Napa Valley peptide company, which also provides financial support for the publication.
Peptide Press is an editorial publication exploring peptides, longevity, performance, emerging biotechnology, and the science shaping human potential. Our goal is to make complex research understandable while preserving the excitement, ambition, and sense of possibility that make these fields worth following.
Editorial content is not meant to provide medical advice, dosing guidance, administration instructions, or recommendations for the use or purchase of any compound.
What we cover
Peptide Press covers peptide science, longevity research, human performance, mitochondrial biology, clinical studies, analytical testing, biotechnology, regulation, and emerging approaches to human health and potential.
We write about individual compounds, mechanisms, new studies, clinical trials, testing methodology, regulatory developments, and broader scientific advances — from mitochondrial peptides and incretin biology to gene editing, regenerative medicine, synthetic biology, and other technologies changing what medicine may be able to accomplish.
Our perspective is optimistic and science-forward. We believe these are among the most exciting areas in modern biology. Our role is not to dampen that enthusiasm, but to explain what the evidence shows, what remains under investigation, and why both are worth understanding.
What we do not do
Editorial content does not provide medical advice, personal dosing guidance, administration or reconstitution instructions, therapeutic recommendations, or instructions for using any compound.
We do not publish personal-use protocols.
Articles about a compound do not link directly to a page selling that compound, and editorial coverage is not selected solely according to Peptinexia's product catalog.
Our relationship with Peptinexia
Peptide Press and Peptinexia LLC share common ownership, and Peptinexia provides financial support for the publication. That relationship is disclosed openly.
Peptide Press maintains a broader editorial scope than Peptinexia's commercial catalog. We cover compounds Peptinexia does not sell, developments outside the peptide industry, unfavorable research findings, regulatory actions, and other subjects based on their scientific and editorial relevance.
Where Peptinexia is specifically referenced within editorial content, the relationship is disclosed. Any link to Peptinexia from editorial content is brand-level rather than a compound-specific product link tied to the subject of an article.
Sourcing standard
We prioritize original research, peer-reviewed studies, clinical-trial registries, regulatory documents, and authoritative institutional sources. Major reviews and high-quality scientific or industry reporting may also be used when they provide important context or cover developments not yet available in peer-reviewed literature.
We distinguish clearly between laboratory, animal, and human evidence. We identify important limitations, unresolved questions, null findings, and regulatory developments while keeping sight of why the underlying science is exciting and worth following.
Sources are listed with each article so readers can examine the underlying evidence themselves.
Corrections
We correct factual errors promptly and note material changes when appropriate. To report an error or raise a sourcing concern, send an email to [email protected].